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A B S T R A C T
Personalized medicines hold promise for many diseases. However, demonstrating the clinical
efficacy and cost effectiveness of these medicines can be difficult. It is essential that decision-
making processes for funding new medicines, including personalized medicines, are both robust
and fit for purpose. We will argue that randomized trials of personalized medicines should be
routinely supplemented with other research methods, such as observational research and
single-arm studies, and that managed-entry funding programs, such as coverage with evidence
development, may offer a means of providing early access to technologies where there is
uncertainty about efficacy, safety, and cost effectiveness. These programs, however, raise a
number of practical and ethical challenges that need to be worked through and resolved.
J Clin Oncol 33:4112-4117. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Advances inmolecular biologyhave led to anumber
of targeted, precision, or personalized medicines
(PMs). The full impact of PMs on health care deliv-
ery is, however, still to be realized.1 This is in part a
result of the difficulty that regulators and funders
have in evaluating the benefits of these medicines
and funding them so that they are available to rele-
vant patient populations.
Both regulators and funders of health care are
chargedwithevaluating theclinical effectiveness and
safety of health technologies. In addition, funders
have an additional mandate: to determine whether
new health care technologies represent value for
moneyandwarrantpublicorprivate funding.How-
ever, assessments of value are often difficult to con-
duct and interpret when it comes to PMs and
associated molecular diagnostic tests.2 This is be-
cause they are often expensive and supported by
limited evidence at the time they are approved by
regulators. In somecases, itmaybe thatnewPMsare
nomore efficacious or cost effective than less expen-
sive alternatives. Alternatively, it might be that they
are more effective and/or better value for money,
but evidence of these benefits is obscured by meth-
ods used in its generation.
It is important that the most suitable methods
are applied when assessing clinical efficacy and cost
effectiveness.3 Failing to assess medicines fairly or
failing to recognize their potential clinical benefits
(where these exist) may create frustration and anxi-
ety forpatientsandtheir carers, especiallywhentheir
life expectancy is short and awareness of seemingly
promising results fromearly studies are presented at
congresses, published in the medical press, and
available via the Internet.4 Physicians may also be
frustratedby the failureof funders toenableaccess to
new medicines and diagnostics. Although compas-
sionate access programs and clinical trials may pro-
vide some with early access, not all patients can be
servedby these programs, and they raise other prob-
lems, such as the potential to undermine traditional
clinical research and regulatory and resource alloca-
tion processes and to create inequities of their own.5
HEALTH TECHNOLOGY ASSESSMENT OF PMS
Health technology assessments (HTAs) are frame-
works within which the safety, efficacy, and cost
effectiveness of new treatments—including new
PMs—are assessed. Health economic and health
care experts conduct HTAs on behalf of a public or
private decision maker, such as the National Insti-
tute for Health and Care Excellence (NICE) in the
United Kingdom, the Pharmaceutical Benefits Ad-
visory Committee (PBAC) in Australia, the Cana-
dian Agency for Drugs and Technology in Health
(CADTH), or the US Centers for Medicare and
Medicaid Services (CMS).
In the United Kingdom, NICE conducts tech-
nology appraisals that assess the clinical and cost
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effectiveness of health technologies, including pharmaceuticals. Its
recommendations about the use of newmedicines andmedical tech-
nologies serve to “give all NHS [National Health Service] patients
access to themost clinically- and cost-effective treatments available.”6
The NHS is legally obliged to fund and resource medicines and treat-
ments recommended byNICE appraisals.6 England also has a Cancer
Drugs Fund,which is “money theGovernment has set aside to pay for
cancer drugs that haven’t been approved by the NICE and aren’t
available within the NHS in England.”7
In Australia, the PBAC is an independent statutory body that
makes recommendations to the Minister for Health about which
medicines shouldandshouldnotbe subsidizedon thePharmaceutical
Benefits Scheme (PBS). If the PBAC makes a positive recommenda-
tion, the government decides whether to fund the medicine, with
prices thennegotiatedby thePharmaceuticalBenefitsPricingAuthor-
ity. In addition to PBS-fundedmedicines, the federal government has
a special program for funding trastuzumab (Herceptin; Genentech,
South San Francisco, CA) for metastatic breast cancer. In Australia,
there is currently a debate as to whether a separate HTA and funding
mechanism should be established for cancer medicines.
InCanada, somemedicines receivecentralized funding,butmost
decisions are made at the provincial level. The CADTH is an “ inde-
pendent, not-for-profit organization responsible for providing health
care decision-makers with objective evidence to help make informed
decisions about the optimal use of health technologies.”8 In Canada,
there is also the pan-Canadian Oncology Drug Review Process, a
“cross-jurisdictional review process for all oncology drugs, based on
Ontario’s existing cancer drug review.”8 Participating provinces “each
make their own final funding decision based on input from theCom-
mittee to Evaluate Drugs (CED) and the CED-Cancer Care Ontario
(CCO) Subcommittee.”8
The United States has a highly diverse, multifaceted health
payer system. CMS and the Agency for Healthcare Research and
Quality conduct HTAs of cancer medicines to determine which
medicines should be funded by CMS and to make recommenda-
tions about which medicines should be subsidized by private
insurers. The responsibilities for regulating and reimbursing com-
mercially available companion diagnostics falls with the US Food
and Drug Administration (FDA), Medicare, and private health
insurance companies. Although some laboratory-developed tests
have not undergone assessment, the FDA-issued “Guidance for
Industry: In Vitro Companion Diagnostic Devices” assists compa-
nies in identifying the need for companion diagnostics at an earlier
stage in the drug development process and in planning for code-
velopment of the drug and companion diagnostic test. The ulti-
mate goal of the guidance is to stimulate early collaborations that
will result in faster access to promising new treatments for patients
living with serious and life-threatening diseases.9
In the United States, rising health care costs and concerns
about safety and quality have led to increasing demands from
regulators and payers for additional evidence that goes beyond that
required by the FDA, such as comparative effectiveness of a new
drug and/or diagnostic as compared with the market leader or
evidence of clinical effectiveness among populations not assessed
in regulatory studies.10 The evolution of Medicare from payer to
prudent purchaser represents a transition froman enabler of access
to new technology toward an evaluator of whether services are
reasonable and necessary.10 CMS has taken steps to evaluate a
number of treatments, such as those for colorectal cancer (irinote-
can, oxaliplatin, cetuximab, and bevacizumab), in collaboration
with the National Cancer Institute (NCI), and this has led to the
identification of a number of high-priority clinical questions.
These uncertainties are being addressed through nine NCI-led
clinical trials, with interim funding provided by Medicare.10
CHALLENGES OF ASSESSING CLINICAL EFFICACY OF PMS
Although systems and strategies to evaluate the efficacy of PMs vary
across different countries and health systems, most of those conduct-
ing HTAs, including HTAs of cancer medicines, prefer systematic
reviews and meta-analyses of randomized controlled trials (RCTs)
over other formsof evidence—generally demanding evidence fromat
least one adequately powered phase III RCT.
The problem, however, is that although RCTs are appropriate
for evaluating drugs used to treat large populations with homoge-
neous disease and in simple treatment settings, they work less well
for small populations and for complex diseases that require multi-
ple forms and lines of therapy, often in conjunction with compan-
ion diagnostics, as occurs in PMs. The applicability of evidence
generated from RCTs to real-life populations will depend on the
degree of alignment between the research and target population in
terms of known and possible unknown clinical and molecular
characteristics. On the basis of probability alone, this potential for
misalignment will increase as RCT participant numbers decrease
or where there is uncertainty surrounding the specific molecular
mechanisms of response.11
Although it is worth noting that there are many examples of
high-quality RCTs that have evaluated targeted cancer therapies,12-14
the efficacyof targeted therapiesmaybe easier to assessusingRCTs for
common cancers, such as breast cancer and non–small-cell lung can-
cer (NSCLC); for example, 20% of women with breast cancer are
human epidermal growth factor receptor 2 (HER2) positive and are
therefore eligible for HER2-directed therapies, and even uncommon
mutations, such as EGFR mutations in NSCLC, occur in sizeable
populations because NSCLC is a common disease.
RCTsmay not, however, be appropriate for all PMs, especially
where the target cancer is of low prevalence and/or genomic sub-
types are uncommon. Trials of PMs are further complicated by the
need to assess codependent diagnostic technologies and by the
ethical imperative to allow patients to switch from one arm of a
study to another. This, particularly when combined with small
numbers of participants, makes it extremely difficult to demon-
strate important study end points, such as overall survival. The
demand for RCT evidence for PMs may, therefore, result in both
type I errors, where ineffective or harmful technologies are made
available, and type II errors, where access to beneficial and cost-
effective therapies is denied.15
CHALLENGES OF ASSESSING VALUE AND COST
EFFECTIVENESS OF PMS
Those conducting HTAs—whether for public or private coverage—
need to consider not only the likely effectiveness of a newmedicine
but also what the medicine costs and its likely impact on overall
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health care spending relative to its clinical benefits. Personalized
oncology medicines can be extremely expensive both for patients
and for health systems, with the price for an average year of cancer
treatment now estimated to be more than $100,000,16,17 so payers
demand not only evidence of efficacy, but also modeling to deter-
mine overall cost effectiveness.
Considerations of cost effectiveness can, however, be extremely
complex for two reasons. First, the cost of a medicine is a social
construct that isderivednot fromits realor trueworthbut rather from
a combination of how much it costs to develop and the need for a
company to make a profit by selling its product at a price the market
will bear.This latter aspect is influencedbyhowunique thedrug is, any
existing competition from already available medicines, the cost of
currently treating the disease for which this drug is used, andwhether
the new drug changes medical practice—for example, such that pa-
tients no longer require hospitalization.
Critically, the perceived cost effectiveness of a new drug will
depend on the degree to which particular outcomes are valued by
payers, patients, governments, and the community at large. This may
preclude an otherwise positive cost-effectiveness assessment if there is
disagreement about the economic factors that need to be taken into
consideration when determining the cost of the drug.18 Given this
complexity, assessments of cost and cost effectiveness cannot always
be fully determined beforemarket entry. This creates an argument for
providing rapid access to potentially beneficial medicines, with post–
market entry assessment of their value and cost effectiveness, aswell as
of their effectiveness.
ACCELERATED APPROVAL AND COVERAGE WITH
EVIDENCE DEVELOPMENT
In the United States, some new oncology treatments are being
approved by the FDA via accelerated approval pathways designed
to “hasten the delivery of products appearing to provide a benefit
for serious or life-threatening illnesses lacking satisfactory treat-
ments.”19Here, approvals are granted after review of surrogate end
points that are considered likely to translate into meaningful clin-
ical benefits. In return, the applicant (usually a pharmaceutical
company) is required to provide evidence that verifies these
benefits and/or safety via phase IIIb and IV studies. Oncology
accelerated approval examples include liposomal doxorubicin,
lipo-cytarabine, and ibritumomab, where confirmatory clinical
evidence was successfully reported to the FDA subsequent to initial
regulatory approval. If clinical benefit is not demonstrated, the
FDA can withdraw approval, as it did with bevacizumab for the
treatment of HER2-negative metastatic breast cancer.20
Those funding newmedicines have also begun exploring mech-
anisms for providing early access tomedicines that are promising and
potentially life saving but have not been demonstrated to be cost
effective. Efforts have included entering into various types ofmanaged
entry arrangements with pharmaceutical companies and prescribers,
aimed at managing the budgetary impact and/or use of funded med-
icines.21 The phrase managed entry describes a range of strategies
including risk sharing, payment for outcomes, performance-based
reimbursement schemes, and various kinds of coveragewith evidence
development (CED).21 CED programs, sometimes referred to as ac-
cess with evidence development or coverage within research, are pro-
cesses by which medicines are reimbursed and prices are negotiated
based on current evidence of efficacy and/or cost effectiveness, with a
view towardgenerating further evidence and subsequently continuing
funding as is, delisting medicines, or adjusting prices on the basis of
emergent evidence.
In the United States, the concept of CED emerged a decade ago
when CMS drafted a new guidance document describing CED. To
date, there has been limited uptake of CED for oncology PMs, with
CMS having selected four colorectal treatments (irinotecan, oxalipla-
tin, cetuximab, and bevacizumab) in collaboration with the NCI to
answer a number of high-priority clinical questions. These uncertain-
ties are currently being addressed through nineNCI-led clinical trials,
with funding of treatment provided byMedicare.10
TheuseofCED-generateddata to list anddelistmedicines and to
adjust prices on the basis of emergent evidence is more developed in
the British Commonwealth and European Union nations than in the
United States. In part, this is because systems in the Commonwealth
and in Europe are fundamentally concerned with the regulation of
drug pricing and universal access to medicines, whereas the United
States is more concerned with the regulation of free enterprise. CED
programs have been endorsed by many international HTA organiza-
tions21 as ameans ofmoving beyond forced yes or no decisions in the
face of uncertain evidence. A review conducted in 2010 identified
nearly 30 forms of CED in Europe, North America, andAustralasia.22
In addition to the previous four colorectal cancer examples of irinote-
can, oxaliplatin, cetuximab, and bevacizumab, additional oncology
treatments include erlotinib, lapatanib, and bevacuzimab in Italy and
bortezomib and sunitinib in theUnited Kingdom; additional nonon-
cology examples include ranibuzumab for wet age-related macular
degeneration and bosanten for pulmonary artery hypertension.10,21
In Australia, the federal government and pharmaceutical indus-
try reached an agreement in 2010 on the principles underpinning
potential CED (referred to there as managed entry) in the PBS. To
justify interim funding through the PBS, pharmaceutical sponsors
need todemonstrate that there is high clinical need, thatnoalternative
treatments are available, and that new definitive data about cost effec-
tiveness will be generated in a timely manner. They also need to
commit to adjusting their prices (in either direction) on the basis of
emergent evidence about cost effectiveness. According to an internal
Department of Health and Ageing memo, dated August 2014, 10
medicines have been reviewed under provisions of managed entry
into thePBS.A similarCEDapproachhas beenused since 1998by the
Australian Medical Services Advisory Committee, which funds med-
ical devices and diagnostics.15
The ethical and sociopolitical justifications for CED programs
are that they balance the interests of clinicians and patients, whowant
early access to newdiagnostic tests andmedicines; payers, whichwant
to address genuine health needs but do not want to pay more for
medicines than they areworth; andpharmaceutical companies,which
want to be paid fairly for their products. As Pearson et al23 argue, such
programs “can play an important, ethically legitimate role in balanc-
ing needs for better evidence . . . with the needs and desires of patients
for rapid access to new technologies.”23(p2924b)
CEDprograms are particularly usefulwhen it comes to the fund-
ing of PMs and treatments for orphan diseases because of the lack of
robust data, as a result of trials not having been conducted or having
beenconducted inonly a smallnumberofpatients. In these situations,
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CED programs can help to promote equity while still maintaining
control over health care budgets.
RESEARCH METHODS TO SUPPORT CED
The evidence generated to support CED programs differs from
data collected via traditional postmarketing surveillance in that it is
more systematic, targeted, and defined in advance by both phar-
maceutical sponsors and funding bodies.15 Evidence generation in
CED also differs from traditional premarketing clinical research in
that RCTs are not necessarily preferred over other research meth-
ods. There are two main alternatives to RCTs that can provide
useful information to inform CED and that may be particularly
important in CED for PMs: observational cohort studies and pro-
spectively designed single-arm studies.
Observational cohort studies track groups of patients defined by
clinical or molecular characteristics, disease status, or treatments re-
ceived. Studies may be prospective or retrospective and canmake use
of data collected directly from patients (primary data sets) or large
administrative andelectronicmedical recorddata sets (secondarydata
sets). Outcomes need to be chosen that can demonstrate clinical ef-
fects in the absence of directly comparative data provided by control
arms within RCTs. For the purpose of descriptive comparisons, ap-
propriately matched contemporary or historical populations and
those treated with previous standards of care may be used.
Alternative approaches to the collection of additional evidence
include single-arm studies. Like observational studies, single-arm
studies require well-matched historical or contemporary control co-
horts and the collection of appropriate outcomes. The application of
methods thatusepropensity scorematchingmaypromote the robust-
ness of data by ensuring like-for-like comparisons between external
control patient groups with those participating in open-label studies.
Although results of single-armstudiesmaybe contrastedwith internal
control cohorts presented from previous RCTs, caution needs to be
taken in the interpretation or contrasting of results. This is because
patients participating in RCTs are likely to be generally fitter, with
better performance status, and will be managed in ways that differ
significantly from those in single-arm studies and in real-world clini-
cal settings.
Althoughboth cohort studies and single-arm studies offer signif-
icant benefits in terms of their capacity to reflect real-world clinical
practice and patient behavior and the speed with which they can be
conducted, there are alsoanumberofdisadvantages to thesemethods.
Observational studies often rely on the existence of high-quality ad-
ministrative andclinical databases,whicharenot always available, and
are easily confounded by unrecognized differences between groups of
patients, and single-arm studies may be expensive, require historic or
parallel standard-of-care cohorts for comparison, and, like RCTs, not
fully reflect natural behavior.
Thesemethodsneedto focusnotonlyoneffectivenessbutalsoon
costs and savings, so the value and cost effectiveness of medicines can
be determined and prices negotiated accordingly. For this to be effec-
tive, clinical, administrative, and insurance databases need to be
linked. Methods for doing so are increasingly the focus of learning
health care systems that arebeingencouraged inmanycountries24 and
of accountable care organizations in the United States.25
PRACTICAL AND ETHICAL CHALLENGES ASSOCIATED WITH
CED PROGRAMS
Although CED programs hold promise as a means of promoting
timely and affordable access to medicines, including many PMs, they
raise a number of practical and ethical challenges. In addition to the
obvious resources needed to establish, run, and govern CED pro-
grams,21 challenges arise in relation to: the effectsofCEDprogramson
evidence-basedmedicine and health resource allocation, the compet-
ing interests of different stakeholders, and possible compromising of
research participants’ interests.
Distortion of Evidence and Health Resource Allocation
Thefirst set of issues raisedbyCEDprograms relates to theuse of
observational and single-arm studies rather thanRCTs. Tomake such
studiesworthwhile andvalid, theirdesign, conduct, andanalysisneeds
tobe rigorous and transparent, particularlywith regard tominimizing
confounding effects and bias needs.
Because these studies also rely on real-worlddata sources, such as
patient registries or administrative databases, and well-matched his-
torical or contemporary comparative cohorts,15,26 they also must be
supported by funding agencies, sponsoring companies, clinicians, ad-
ministrators, and insurers.15 These studies should also complement,
rather than replace, RCTs.21,27
Failure to follow through on CED programs might also un-
dermine the capacity for budgetary control if disinvestment or
price reductions do not follow when medicines are found to be
poor value for money. The reality is that once patients and clini-
cians have access to, and are familiar with, a new technology,
disinvestment is highly unlikely to occur or is likely to be rigorously
resisted by pharmaceutical companies.28,29 If disinvestment does
not occur, CED programs will be responsible for exacerbating the
very thing they are designed to prevent—medical practice that is
neither evidence based nor cost effective.
Competing Stakeholder Interests
Although CED theoretically represents a compromise among
various stakeholder groups, there are likely to be tensions between
different and potentially competing interests. Companies may
wish to obtain the highest prices possible, and payers may wish to
pay as little as possible; manufacturers of generic medicines worry
that these programs exist to promote early access to expensive
patented medicines,28 and even manufacturers of patented medi-
cines may worry that competitors will make use of the evidence
they generate as part of a CED program.21
The criteria for instituting CED, such as high clinical need, and
other criteria, such as timely returnof research results,may alsonot be
easily defined andmay be contested.28 Stakeholdersmay also disagree
about the funding of new diagnostic tests in CED programs, and
pharmaceutical companies may disagree with payers about how to
interpret emergent evidence—particularlywhether it justifiesmainte-
nance, escalation, or reduction in drug prices.
The negative effects of these disagreements are likely to be
exacerbated by the fact that negotiations about CED programs—
particularly discussions of drug prices—may be commercially confi-
dential. Given the centrality of price negotiations to CED programs,
commercial confidentialitymakes it impossible for funding organiza-
tions to be transparent in their decision-making processes. This, in
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turn,may undermine their inclusiveness, their perceived trustworthi-
ness, and their legitimacy in the eyes of external stakeholders to thwart
efforts on the part of funding agencies to satisfy the principles of
accountability for reasonableness.21
Potential Compromising of Research
Participants’ Interests
The third group of issues raised by CED programs relates to
ethical oversight of these programs. The question has been raised, for
example, about what kinds of CED programs count as research (eg,
whether participation in registries counts as research or simply as
quality improvement) and what, if any, consent and ethical oversight
are needed.23 A related question is whether it is ethical to insist that
patients participate in research as a condition of coverage. Although
clinical trials often provide the onlymeans of accessing new therapies,
CED programs are generally predicated on the basis that the new
therapy is likely to be beneficial—meaning that there is unlikely to be
genuine equipoise.23
It could also be argued that concerns about exploiting research
participants in this way are not unique to CED programs—which are
simply one component of increasingly popular learning health care
systems, in which research and clinical practice are integrally inter-
twined.30 One difference, however, is that in the context of a CED
program, there is likely to be at least some evidence of benefit associ-
ated with the new therapy (ie, there is unlikely to be genuine equi-
poise), so someresearchparticipantswillbepredictablydisadvantaged
relative to other research participants.
DISCUSSION
Medical regulators and funders worldwide face seemingly impossible
challenges stemming from advances in medical science, such as PMs,
but limited capacity to approve and fund all such advances. It is
essential that decisions regarding the regulation and funding of any
new medical therapies be made on the basis of clear criteria and
according to processes that are transparent and ethically justifiable.
Until recently, HTA has relied on RCTs, systematic reviews, meta-
analyses, and cost-effectiveness analyses, all conducted before market
entry. Such methods are, however, particularly difficult to apply to
medicines for patients with orphan diseases and to some PMs—
particularly given the lackof clarity as tohow theworthofPMs should
be determined and the lack of transparency surrounding both the
setting of drug prices and negotiations between industry and third-
party payers. To strike a balance between the needs of patients, physi-
cians, funders, and industry, differentmechanisms for evaluation and
translation need to be used. These include alternative forms of clinical
trial design, suchasobservational researchandsingle-armstudies, and
flexible strategies for managing access to market, such as CED. These
alternatives, however, raise issues of their own and, if not imple-
mented with great care, may ultimately undermine evidence-based
medicine and systems for controlling health budgets.
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